Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit™.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai Inc., Exelixis, and Prometheus Laboratories Inc.

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward PER Pulse™ Recap

PER Pulse™ Recap

1 of 3
PER Pulse™ Recap

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, FL. In this online activity, expert faculty discuss standards of care and emerging strategies for renal cell carcinoma (RCC). It features commentary on:

Targeted therapy in the adjuvant and relapsed metastatic settings by Robert Figlin, MD

Immunotherapy for RCC in 2017 by David McDermott, MD

Informed therapeutic sequencing by Sumanta Pal, MD

Non‒clear cell RCC by Bernard Escudier, MD

A look ahead in RCC, by Toni Choueiri, MD

This first of 1 PER Pulse™ Recaps summarizing the online program focuses on Dr. Figlin’s answers to questions about adjuvant targeted therapy for RCC, during which he discussed:

His approach toward a 65-year-old male who underwent partial nephrectomy for a pT3b, Fuhrman grade 3 RCC tumor and who has good performance status

Rationale for early treatment of micrometastatic disease in RCC and unanswered questions regarding use of adjuvant therapy

The importance of making the best decision with the options available to you at each step of decision making

The future of adjuvant therapy (eg, investigations of immunotherapeutics)

2 of 3
PER Pulse™ Recap

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, FL. In this online activity, expert faculty discuss standards of care and emerging strategies for renal cell carcinoma (RCC). It features commentary on:

Targeted therapy in the adjuvant and relapsed metastatic settings by Robert Figlin, MD

Immunotherapy for RCC in 2017 by David McDermott, MD

Informed therapeutic sequencing by Sumanta Pal, MD

Non‒clear cell RCC by Bernard Escudier, MD

A look ahead in RCC, by Toni Choueiri, MD

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on Dr. Pal’s answers to questions about sequencing therapies for metastatic RCC, during which he discussed:

Interesting results from a circulating tumor DNA analysis, presented at ASCO GU 2017, that may influence treatment selection and drug development in the future

Compelling data from a randomized phase II study of front-line bevacizumab + atezolizumab for patients with advanced RCC that suggested that this combination may preferentially benefit patients who are PD‒L1-positive

3 of 3
PER Pulse™ Recap

Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field Forward is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, FL. In this online activity, expert faculty discuss standards of care and emerging strategies for renal cell carcinoma (RCC). It features commentary on:

Targeted therapy in the adjuvant and relapsed metastatic settings by Robert Figlin, MD

Immunotherapy for RCC in 2017 by David McDermott, MD

Informed therapeutic sequencing by Sumanta Pal, MD

Non‒clear cell RCC by Bernard Escudier, MD

A look ahead in RCC, by Toni Choueiri, MD

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on Dr. McDermott’s answers to questions about immunotherapy in RCC, during which he discussed:

His approach toward a 66-year-old male with metastatic RCC who progressed while on sunitinib therapy, experienced gastrointestinal toxicity while on second-line nivolumab, and eventually developed asymptomatic progression while on nivolumab.

Circumstances where an endoscopy/colonoscopy would be appropriate for a patient experiencing immune-related gastrointestinal toxicity.